Purpose. The aim of this study was to compare the in vitro activity of ampicillin and moxifloxacin against six isolates selected from 154 invasive clinical isolates of Listeria monocytogenes and evaluate their intra-and extracellular activities with achievable central nervous system concentrations obtained using Monte Carlo simulations with conventional and unconventional dosages.
INTRODUCTION
Listeria monocytogenes has tropism for the brain and meninges where meningeal infection, with or without focal neurological signs, is the most common presentation of central nervous system (CNS) infection; meningoencephalitis and abscesses are less frequent presentations [1] . The mortality rate of neuroinvasive listeriosis is around 25 % and neurologic sequelae occur in 13 % of the patients [2] . These unavoidable results are due to the CNS infections that occur mainly in immunocompromised patients and therefore successful treatment is not always possible. Currently, the treatment guidelines for L. monocytogenes infection from the Infectious Diseases Society of America do not consider CNS location as a special case for treatment, as is the case with Streptococcus pneumoniae infections. Moreover, neurolisteriosis is associated with a high mortality rate, despite the recommendation of intravenous ampicillin (12 g day -1 ) as the treatment of choice in listerial meningitis [3] . This could be due to the fact that in meningitis beta-lactam activity is concentration-dependent [4] ; therefore, the ampicillin dosage would be the most critical factor when treating listerial meningitis [5] due to its low meningeal penetration [6] .
Moxifloxacin reaches high concentrations in cerebrospinal fluid (CSF) [7] and is highly active against L. monocytogenes due to its rapid bactericidal effect at low concentrations [8] [9] [10] [11] . It could therefore be an alternative to ampicillin for listeriosis treatment.
Most of the in vitro studies have been conducted with the strain serovar 1/2a (EGD-e, a derivative of strain EGD) or with uncharacterized strains. The poor clinical outcome in CNS listerial infections could be related to the great diversity of serotypes and/or epidemic clones involved in listerial meningitis.
Therefore, the treatment of L. monocytogenes CNS infections still requires optimization. Thus, the aim of this study was to compare the in vitro activity of ampicillin and moxifloxacin against six isolates selected from 154 clinical isolates and to evaluate the intra-and extracellular activities of both antibiotics at achievable CNS concentrations after conventional and unconventional dosages. 
METHODS

Clinical isolates
Antimicrobial susceptibility testing
MICs and minimal bactericidal concentrations (MBCs) of ampicillin and moxifloxacin were determined by using the broth microdilution method in cation-adjusted MuellerHinton broth with 5 % lysed horse blood based on Clinical and Laboratory Standards Institute (CLSI) criteria [13, 14] . A 0.5 McFarland bacterial inoculum was used. Streptococcus pneumoniae ATCC 49619 was used as a quality control strain. The modal MICs and MBCs obtained were reported as MIC for 50 and 90 % of the organisms, respectively (MICs 50/90 ) and MBC for 50 and 90 % of the organisms respectively (MBCs 50/90 ).
In silico study of the ampicillin and moxifloxacin concentrations in CSF by Monte Carlo simulation A Monte Carlo simulation over 10 000 individuals was performed for conventional doses of ampicillin (200 mg kg À1 day
À1
) and moxifloxacin (400 mg day
) and nonconventional doses of 400 mg kg À1 day À1 [15] and 800 mg day À1 [16] , respectively, to determine the CSF concentrations of both ampicillin and moxifloxacin. The Monte Carlo simulation generates a set of pharmacokinetics (PK) parameter values through random sampling of values within the predefined PK parameter distribution for each simulated patient.
We used an application built in Microsoft Excel (Microsoft Corp., Redmond, WA) for a 70 kg standard adult patient with normal renal function, based on the following equation: C max,CSF,free =(DoseÂCSF penetration rate)/V ss , where C max was the maximum free concentration achieved in the CSF (mg l À1 ), Dose was the dose of antibiotic (mg), CSF penetration rate was percentage of penetration into the CNS and V ss was the antimicrobial volume of distribution at steady state (l kg
). In this model, all the PK parameters are assumed to be log-normal distributed in the population. PK and CSF penetration parameters were obtained as the mean values and coefficients of variation of previously published data [7, [17] [18] [19] .
From the results of C max obtained, the median value and its range were calculated, which have been used in this study.
Moxifloxacin and ampicillin extracellular bactericidal activity determination The antimicrobial extracellular activity of both antibiotics was studied on six strains representative of major serotypes and ECs [12] : ID28 (1/2b, no EC); ID49 (4b, ECII); ID57 (1/ 2a, no EC); ID60 (4b, ECI); ID79 (1/2a, ECIII); ID118 (4b, no EC).
The extracellular bactericidal activity was measured by time-kill curves according to CLSI methodology [14] , with an incubation time of 48 h [8] . Six antibiotic concentrations were used: 1ÂMIC, 3ÂMIC and the median maximum CSF concentrations (C max,free ) of moxifloxacin and ampicillin obtained through Monte Carlo simulation with intravenous dosages of moxifloxacin (400-800 mg day
) and ampicillin (200-400 mg kg À1 day
).
Bacterial counts were determined in duplicate at 3, 6, 24 and 48 h. Bactericidal activity was defined as the killing of more than 99.9 % (3 log 10 ) of the initial inoculum after 24-48 h of incubation. The killing rate was defined as a decrease in the initial inoculum within the first 3 h. Additionally, the area under the killing-curve (AUKC) reduction of the inoculum at 6 h with both antibiotics was studied, as described by MacGowan et al. [20] .
Kill-curves were modelled and studied using GraphPad Prism 5.0 software (GraphPad Software).
Moxifloxacin and ampicillin intracellular activity determination
The intracellular activities of both antibiotics were determined on the same strains used to assess its extracellular activity based on the model published by Lepe et al. [21] . The type II pneumocyte cell line A549 derived from a human lung carcinoma was infected for 1 h with an inoculum of 10 8 c.f.u. ml À1 of each L. monocytogenes strain, at an m.o.i. of 10 : 1 bacteria per cell. Subsequently, the infected A549 cells were exposed during 1 and 24 h to the median maximum CSF concentration (C max,free ) obtained by Monte Carlo simulation of ampicillin and moxifloxacin with intravenous dosages of 200-400 mg kg À1 day À1 and 400-800 mg day
À1
, respectively. Diluted lysates were plated onto blood agar (Columbia blood agar; Becton Dickinson Microbiology Systems, Cockeysville, MD) and incubated at 37 C for 24 h to enumerate viable bacteria. Cellular integrity was checked every time and the rate of infection was determined by microscopic examination of May-Grunwald-Giemsastained cells. The experiments were performed in triplicate and the results were expressed as the percentage of viable bacteria over the control. , respectively, as predicted by this model. The free CSF moxifloxacin median values for dosages of 400 and 800 mg day À1 were 1.14 mg l À1 within a range from 0.69 to 1.71 mg l
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À1
, and 2.21 mg l À1 with a range from 1.68 to 3.59 mg l
, respectively.
Since the median value of the C max,free predicted for moxifloxacin was 1.14 mg l À1 with the 400 mg day À1 dose, which is very close to the 3ÂMIC value (1.5 mg l À1 ), we selected this concentration for the extra-and intracellular bactericidal activity studies.
Extracellular bactericidal activity of ampicillin and moxifloxacin
The reduction of extracellular inoculum obtained with different ampicillin and moxifloxacin concentrations against the six strains (six isolates averaged; MIC=0.25-0.5 mg l À1 ) is shown in Fig. 1 . Both antibiotics showed bactericidal activity against the extracellular forms of L. monocytogenes. However, this bactericidal effect was faster with moxifloxacin than with ampicillin.
The median log of the inoculum reduction of the six strains studied at 24 h with a 1ÂMIC ampicillin concentration was 0.2 log 10 (range from 0.7 to À0.9) while for 3ÂMIC, C max,200 and C max,400 concentrations were À1.3 log 10 (range from À0.5 to À2.7), À1.5 log 10 (range from À0.6 to À3.3) and À1.8 log 10 (range from À0.7 to À3.5), respectively (Table 1) .
At 48 h, the median log reduction rose to bactericidal values for all serotypes and all concentrations except for 1ÂMIC, while for 3ÂMIC, C max,200 and C max,400 concentrations were À3.8 log 10 (range from À2.8 to À4), À4.1 log 10 (range from À3.8 to À4.6) and À4.2 log 10 (range from À3.9 to À5.2), respectively.
The killing-rate (3 h log 10 inoculum reduction) was close to zero for all strains and concentrations tested ( Table 1 ).
The median reduction in the AUKC at 6 h of incubation was similar in the six strains studied ranging from À10 % reduction, with 0.5 mg l À1 (1ÂMIC), to À13 % for the remaining concentrations ( Table 2 ).
The bactericidal effect of moxifloxacin (Table 1 ) was evident after 6 h of incubation with 3ÂMIC and C max,800 concentrations with a median log of inoculum reductions of À2.8 log 10 (range from À1.9 to À4.6) and À3 log 10 (range from À2.1 to À4) respectively. At 24 h, the bactericidal effect was also demonstrated even with 1ÂMIC concentration with a median log of inoculum reductions of À3.8 log 10 (range from À2.2 to À4.7).
The killing-rate varied between À0.3 log 10 (range from 0.1 to À1.3) with 1ÂMIC, to À1.4 log 10 (range from À0.6 to À2.7) and À1.5 log 10 (range from À0.9 to À2.8) with 3ÂMIC, and C max,800 concentrations, respectively.
The AUKC reduction at 6 h of incubation (Table 2) varied from À20 % (range from À10 % to À33 %), À28 % (range from À15 to À47 %) and À31 % (range from À18 % to À47 %) with 1ÂMIC, 3ÂMIC and C max,800 concentrations, respectively.
The combination of both antibiotics after 24 h and 48 h did not show any synergistic effect when compared to the most active antibiotic alone, moxifloxacin (Fig. 1, Table 1 ). At 24 h, the bactericidal effect of the combination was lower than moxifloxacin alone, À3.1 log 10 (range from À1.8 to À3.8) at 1ÂMIC, À3.8 log 10 (range from À2 to À4.4) at 3ÂMIC and À4.3 log 10 (range from À3.1 to À5.4) at C max concentrations.
The killing-rate ranged from À0.2 log 10 at 1ÂMIC concentration, À0.4 log 10 at 3ÂMIC concentrations and À0.2 log 10 at peak concentrations of both antibiotics, which were lower than those obtained with moxifloxacin.
The AUKC reduction at 6 h of incubation was very homogeneous among the six strains studied, ranging from À15 % to À16 % ( Table 2) . There were no differences in the extracellular activity among strains belonging to different serotypes and/or ECs.
Intracellular activity of ampicillin and moxifloxacin
The intracellular inoculum reductions obtained with the different concentrations of ampicillin and moxifloxacin against the six strains studied, taken as a whole, are shown in Fig. 2 . Both antibiotics achieved significant intracellular inoculum reductions after 1-24 h of incubation; however, moxifloxacin becomes rapidly bactericidal, achieving much greater inoculum reductions in the first hour.
A median reduction of the intracellular inoculum of À25.4 % (range from À16.7 % to À30 %) was obtained with ampicillin after 1 h of incubation with C max,200 and increased to À60.6 % (range from À35.3 % to À68.9 %) with C max,400 concentration. Nearly 100 % 
Median value of all the strains reduction in the intracellular inoculum of the six strains was obtained with the same concentrations after 24 h (Table 3) .
A median reduction of the intracellular bacterial inoculum of À39.1 % was obtained with moxifloxacin after 1 h of incubation (range from À28.6 % to À64 %) with C max,400 concentration and increased to À80.5 % (range from 50 to 87.8 %) with C max,800 concentration. Again, almost 100 % reduction of the intracellular inoculum occurred in all the strains with both concentrations after 24 h (Table 3) .
The difference in the intracellular inoculum reduction between ampicillin and moxifloxacin at 1 h of incubation was statistically significant for C max,200/400 (Mann-Whitney test, P=0.010) and C max,400/800 concentrations (Mann-Whitney test, P=0.035).
The intracellular activity was similar against all isolates, and no differences were found among the serotypes or ECs.
DISCUSSION
The results of this study show higher in vitro activity of moxifloxacin than ampicillin against extracellular and intracellular forms of L. monocytogenes with achievable CSF concentrations.
Few studies have investigated the in vitro susceptibility of L. monocytogenes to moxifloxacin. The MIC 50/90 values of our isolates are similar to those reported previously. Grayo et al.
[8] found a MICs 50/90 of 0.5 mg l À1 and 0.75 mg l À1 for moxifloxacin in a wide range of isolates from different sources (human, food and environmental) with antibiotic gradient strips. Similar results were obtained in another study in which only 26 isolates were tested [22] . Furthermore, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) modal moxifloxacin MIC 50/90 values are only one dilution above our MIC 50/90 values.
All isolates were susceptible to ampicillin, according to EUCAST ( 1 mg l
À1
) and CLSI ( 2 mg l À1 ) criteria, as previously reported in Europe [23] [24] [25] [24, 27] .
Few studies have evaluated the bactericidal activity of moxifloxacin by time-kill curves against L. monocytogenes. Grayo et al. [8] , using a virulent 1/2a serotype, showed a 3 log 10 c.f.u. ml À1 reduction of the initial inoculum after 6 h of incubation, with a higher rate of bacterial killing with 4ÂMIC and C max serum concentrations. Seral et al. [28] also found similar results, with a 2 log 10 reduction after 5 h of incubation with 3.4 mg l À1 of moxifloxacin. These results are similar to ours where, with C max.400/800 , the median inoculum reduction ranged between 2.9 and 3.3 log 10 , respectively. Carryn et al. [29] also highlight the bactericidal activity after 24 h of incubation with clinically relevant concentrations (4 mg l À1 ), with 3.9 to 5.5 median log 10 reductions.
No bactericidal activity was observed after 24 h with ampicillin, although a median log 10 inoculum reduction from 3.6 to 4.4 with !1.5 mg l À1 (3ÂMIC) concentration is reached at 48 h. These data contradict clinical experience where ampicillin and penicillin are effective in L. monocytogenes meningitis treatment [30] . However, Appleman et al. [31] showed that prolonged incubation with ampicillin has a bactericidal effect on L. monocytogenes, similar to that , the use of the former dose is not justified.
Although both antibiotics exert a bactericidal effect on extracellular forms of L. monocytogenes, moxifloxacin is faster than ampicillin [5, 19] and this rapid bactericidal activity could explain the positive clinical evolution of patients, especially those with deficient cellular immunity [34] .
Two studies have demonstrated the antagonism of the combination of beta-lactams plus quinolones against L. monocytogenes, in vitro and in a neutropenic mouse model [35, 36] . In our study, the combination of three fixed concentrations of both antibiotics did not show any synergistic effect, discouraging this combination for treatment.
Our study demonstrates the robust intracellular activity of moxifloxacin with median reductions of the intracellular inoculum ranging from 39 to 80 % after 1 h of incubation, depending on the strain and the antibiotic concentration used. At 24 h, intracellular sterilization was achieved with concentrations of C max,400 and C max,800 . Other studies also show that moxifloxacin exhibits rapid concentrationdependent bactericidal activity against intracellular forms of L. monocytogenes [8, 11, 29] . Although ampicillin produces a lower intracellular inoculum reduction than moxifloxacin with concentrations of C max,200 and C max,400 in the first hour of incubation, it becomes very high (98.6 and 99.9 %) after 24 h. The intracellular activity of both antibiotics at 24 h was similar, with nearly 100 % reduction of the intracellular inoculum. However, the intracellular activity of moxifloxacin at 1 h is significantly faster than ampicillin. Furthermore, moxifloxacin activity was superior to ampicillin in animal models [37] , and was highly effective in experimental models of meningitis [9, 10] . This activity difference in the first hour of incubation may be due to the fact that the beta-lactams, at least in theirionized form, such as ampicillin, diffuse slowly through cell membrane and accumulate in the cytosol [38] .
Several authors have shown that the intracellular effectiveness of ampicillin is greater than the extracellular activity, especially at 24 h [39] . We have also demonstrated a very low median log 10 inoculum reduction with the extracellular activity of ampicillin at 24 h in comparison with the 99 % of the intracellular reduction. This could be explained by the induction of pyroptosis, a form of cell death, that is triggered when the intracellular forms of L. monocytogenes are lysed by ampicillin [40] .
Therefore, the results of this study demonstrate the rapid bactericidal activity of moxifloxacin against extracellular and intracellular forms of L. monocytogenes with concentrations achievable in the CNS compared to current treatment with ampicillin, suggesting that moxifloxacin could be a promising alternative for the treatment of neurolisteriosis. However, these results should be confirmed in animal models and future clinical trials. 
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